Advances in the management of HER2-positive early breast cancer.
about
Panomics for Precision Medicine.Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer.Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles.Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
P2860
Advances in the management of HER2-positive early breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Advances in the management of HER2-positive early breast cancer.
@en
Advances in the management of HER2-positive early breast cancer.
@nl
type
label
Advances in the management of HER2-positive early breast cancer.
@en
Advances in the management of HER2-positive early breast cancer.
@nl
prefLabel
Advances in the management of HER2-positive early breast cancer.
@en
Advances in the management of HER2-positive early breast cancer.
@nl
P2093
P2860
P1476
Advances in the management of HER2-positive early breast cancer.
@en
P2093
Javier Cortés
José Baselga
Robert E Coleman
Wolfgang Janni
P2860
P304
P356
10.1016/J.CRITREVONC.2017.10.001
P577
2017-10-04T00:00:00Z